Ping-Li Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ping-Li Sun has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Hongwen Gao
Department of pathology the Second Hospital of Jilin University Changchun China
16 shared publicationsMeng Jia
Department of Pathology, The Second Hospital of Jilin University, Changchun, China
14 shared publicationsShili Yu
Department of Pathology, The Second Hospital of Jilin University, Changchun, China
9 shared publications- Hongwen Gao
Department of Pathology, The Second Hospital of Jilin University, Changchun, China
7 shared publications Lanqing Cao
Department of Pathology, The Second Hospital of Jilin University, Changchun, China
7 shared publications- Hongwen Gao
Department of Pathology, The Second Hospital of Jilin University, Jilin, China
5 shared publications
Latest Publications
- 13 October 2026
- Published by Wiley in International Journal of Cancer
Molecular and Clinicopathological Characteristics Predict Fertility‐Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrioid Endometrial Cancer
Rising incidence of endometrial cancer among young women has increased the demand for fertility‐sparing treatment (FST) in patients with endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC). However, approximately 20%–30% of patients exhibit progesterone resistance, and reliable predictive biomarkers remain inadequately defined. Therefore, we aimed to identify biomarkers associated with treatment response and prognosis in patients undergoing FST. In this retrospective study, we analyzed 161 patients undergoing mainly progestin‐based FST, including 125 with EAH and 36 with G1 EEC. Molecular classification, pretreatment pathological morphology, hormone receptor expression, oncological outcomes, recurrence, and reproductive outcomes were evaluated. According to molecular classification, the cohort included POLE mut ( n = 2), NSMP ( n = 143), MMRd ( n = 11), and p53abn ( n = 5). Over a median treatment duration of 7 months, molecular classification significantly stratified complete response (CR) rates ( p = 0.027), with distinct cumulative CR curves ( p = 0.034). Patients with EEC showed lower CR rates than those with EAH ( p < 0.001). Reduced CR was associated with extensive lesions, larger lesion diameter, proliferative endometrial background, papillary structure, and squamous metaplasia, whereas morular metaplasia and high estrogen receptor (ER)/progesterone receptor (PR) expression predicted higher CR rates. Multivariate analysis identified MMRd and squamous metaplasia as independent predictors of recurrence. Within the NSMP subgroup, pathological morphology and PR expression further refined risk stratification. Pregnancy outcomes were comparable across molecular subtypes. These findings suggested that integrating molecular classification with clinicopathological characteristics can improve prognostic assessment and support individualized management for patients undergoing FST.
- 13 October 2026
- Published by Wiley in International Journal of Cancer
Molecular and Clinicopathological Characteristics Predict Fertility‐Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrioid Endometrial Cancer
Rising incidence of endometrial cancer among young women has increased the demand for fertility‐sparing treatment (FST) in patients with endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC). However, approximately 20%–30% of patients exhibit progesterone resistance, and reliable predictive biomarkers remain inadequately defined. Therefore, we aimed to identify biomarkers associated with treatment response and prognosis in patients undergoing FST. In this retrospective study, we analyzed 161 patients undergoing mainly progestin‐based FST, including 125 with EAH and 36 with G1 EEC. Molecular classification, pretreatment pathological morphology, hormone receptor expression, oncological outcomes, recurrence, and reproductive outcomes were evaluated. According to molecular classification, the cohort included POLE mut ( n = 2), NSMP ( n = 143), MMRd ( n = 11), and p53abn ( n = 5). Over a median treatment duration of 7 months, molecular classification significantly stratified complete response (CR) rates ( p = 0.027), with distinct cumulative CR curves ( p = 0.034). Patients with EEC showed lower CR rates than those with EAH ( p < 0.001). Reduced CR was associated with extensive lesions, larger lesion diameter, proliferative endometrial background, papillary structure, and squamous metaplasia, whereas morular metaplasia and high estrogen receptor (ER)/progesterone receptor (PR) expression predicted higher CR rates. Multivariate analysis identified MMRd and squamous metaplasia as independent predictors of recurrence. Within the NSMP subgroup, pathological morphology and PR expression further refined risk stratification. Pregnancy outcomes were comparable across molecular subtypes. These findings suggested that integrating molecular classification with clinicopathological characteristics can improve prognostic assessment and support individualized management for patients undergoing FST.
- Open Access
- 14 July 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 211, 162-170
Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations
- 14 July 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 211, 162-170
Open AccessFolate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations
- Open Access
- 17 March 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening
Accurate assessment of Human Epidermal Growth Factor Receptor 2 (HER2) immunohistochemistry (IHC) expression, particularly the precise identification of
- 17 March 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessAI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening
Accurate assessment of Human Epidermal Growth Factor Receptor 2 (HER2) immunohistochemistry (IHC) expression, particularly the precise identification of
- Open Access
- 26 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Uterine tumors with sex cord-like elements: a clinicopathologic study of 19 cases
Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) are rare uterine tumors predominantly made up of sex cord-like elements. However, sex cord-lik
- 26 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessUterine tumors with sex cord-like elements: a clinicopathologic study of 19 cases
Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) are rare uterine tumors predominantly made up of sex cord-like elements. However, sex cord-lik
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications
Ge Y, et al. J Gynecol Oncol. 2026 ;37:e73. https://doi.org/10.3802/jgo.2026.37.e73
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Open AccessHomologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications
Ge Y, et al. J Gynecol Oncol. 2026 ;37:e73. https://doi.org/10.3802/jgo.2026.37.e73
- Open Access
Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis
Malignant mesothelioma of the tunica vaginalis testis (MMTVT) is a rare malignancy originating from mesothelial cells of the testicular tunica vaginalis. Due to its insidious onset and local aggressiveness, most patients are diagnosed at an advanced stage. The treatment modalities for MMTVT primarily include surgery, chemotherapy, and radiotherapy. With the advent of immunotherapy, patient survival has further improved. To standardize and homogenize the diagnosis and treatment of MMTVT in China, the Chinese Alliance of Research for Mesothelioma, combining existing research evidence and nationwide expert opinions, has formulated a national expert consensus on the clinical diagnosis and treatment of MMTVT. This consensus encompasses epidemiology, diagnosis, treatment, prognosis, and follow‐up.
Open AccessExpert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis
Malignant mesothelioma of the tunica vaginalis testis (MMTVT) is a rare malignancy originating from mesothelial cells of the testicular tunica vaginalis. Due to its insidious onset and local aggressiveness, most patients are diagnosed at an advanced stage. The treatment modalities for MMTVT primarily include surgery, chemotherapy, and radiotherapy. With the advent of immunotherapy, patient survival has further improved. To standardize and homogenize the diagnosis and treatment of MMTVT in China, the Chinese Alliance of Research for Mesothelioma, combining existing research evidence and nationwide expert opinions, has formulated a national expert consensus on the clinical diagnosis and treatment of MMTVT. This consensus encompasses epidemiology, diagnosis, treatment, prognosis, and follow‐up.
- Open Access
- 24 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1516264
Digital pathology and artificial intelligence in renal cell carcinoma focusing on feature extraction: a literature review
The integrated application of artificial intelligence (AI) and digital pathology (DP) technology has opened new avenues for advancements in oncology and molecular pathology. Consequently, studies in renal cell carcinoma (RCC) have emerged, highlighting potential in histological subtype classification, molecular aberration identification, and outcome prediction by extracting high-throughput features. However, reviews of these studies are still rare. To address this gap, we conducted a thorough literature review on DP and AI applications in RCC through database searches. Notably, we found that AI models based on deep learning achieved area under the curve (AUC) of over 0.93 in subtype classification, 0.89-0.96 in grading of clear cell RCC, 0.70-0,89 in molecular prediction, and over 0.78 in survival prediction. This review finally discussed the current state of researches and potential future directions.
- 24 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1516264
Open AccessDigital pathology and artificial intelligence in renal cell carcinoma focusing on feature extraction: a literature review
The integrated application of artificial intelligence (AI) and digital pathology (DP) technology has opened new avenues for advancements in oncology and molecular pathology. Consequently, studies in renal cell carcinoma (RCC) have emerged, highlighting potential in histological subtype classification, molecular aberration identification, and outcome prediction by extracting high-throughput features. However, reviews of these studies are still rare. To address this gap, we conducted a thorough literature review on DP and AI applications in RCC through database searches. Notably, we found that AI models based on deep learning achieved area under the curve (AUC) of over 0.93 in subtype classification, 0.89-0.96 in grading of clear cell RCC, 0.70-0,89 in molecular prediction, and over 0.78 in survival prediction. This review finally discussed the current state of researches and potential future directions.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (6)
Navigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma
Xing T, et al. J Gynecol Oncol. 2025 May;36:e123. https://doi.org/10.3802/jgo.2025.36.e123
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (6)
Open AccessNavigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma
Xing T, et al. J Gynecol Oncol. 2025 May;36:e123. https://doi.org/10.3802/jgo.2025.36.e123
- Open Access
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1438179
New insights into acinic cell carcinoma of the breast: clinicopathology, origin of histology, molecular features, prognosis, and treatment
Acinic cell carcinoma (AciCC) of the breast is a rare malignant epithelial neoplasm, with approximately 60 cases reported in the literature. It predominantly affects women and exhibits significant histological heterogeneity. The diagnosis of breast AciCC is primarily based on the presence of eosinophilic and/or basophilic granular cytoplasm and markers of serous acinar differentiation. Despite being considered a low-grade variant of conventional triple-negative breast cancer (TNBC), over 25% of patients with breast AciCC have adverse clinical outcomes. Additionally, in early research, microglandular adenosis (MGA) and atypical MGA were considered potential precursors for various breast cancers, including intraductal carcinoma, invasive ductal carcinoma, adenoid cystic carcinoma, metaplastic carcinoma, and AciCC. Similarly, some studies have proposed that breast AciCC should be considered a type of carcinoma developing in MGA with acinic cell differentiation rather than a distinct entity. Therefore, the pathogenesis of breast AciCC has not yet been clarified. Moreover, to the best of our knowledge, the literature has not summarized the latest prognosis and treatment of breast AciCC. In this review, we synthesized the current literature and the latest developments, aiming at exploring the clinicopathology, histological origin, molecular features, prognosis, and treatment of breast AciCC from a novel perspective.
- 2 September 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1438179
Open AccessNew insights into acinic cell carcinoma of the breast: clinicopathology, origin of histology, molecular features, prognosis, and treatment
Acinic cell carcinoma (AciCC) of the breast is a rare malignant epithelial neoplasm, with approximately 60 cases reported in the literature. It predominantly affects women and exhibits significant histological heterogeneity. The diagnosis of breast AciCC is primarily based on the presence of eosinophilic and/or basophilic granular cytoplasm and markers of serous acinar differentiation. Despite being considered a low-grade variant of conventional triple-negative breast cancer (TNBC), over 25% of patients with breast AciCC have adverse clinical outcomes. Additionally, in early research, microglandular adenosis (MGA) and atypical MGA were considered potential precursors for various breast cancers, including intraductal carcinoma, invasive ductal carcinoma, adenoid cystic carcinoma, metaplastic carcinoma, and AciCC. Similarly, some studies have proposed that breast AciCC should be considered a type of carcinoma developing in MGA with acinic cell differentiation rather than a distinct entity. Therefore, the pathogenesis of breast AciCC has not yet been clarified. Moreover, to the best of our knowledge, the literature has not summarized the latest prognosis and treatment of breast AciCC. In this review, we synthesized the current literature and the latest developments, aiming at exploring the clinicopathology, histological origin, molecular features, prognosis, and treatment of breast AciCC from a novel perspective.
- Open Access
- 24 July 2024
- Published by Springer Nature in Diagnostic Pathology
- Vol. 19 (1) , 1-8
Elucidating the nature of acinic cell carcinoma of the breast with high-grade morphology: evidence from case report
Background: Acinic cell carcinoma (AciCC) of the breast is a rare subtype of breast cancer. It was considered a low-grade triple-negative breast cancer (TNBC) with the potential to progress or transform into a high-grade lesion because of the molecular similarities with conventional aggressive TNBC in several genetic studies. Microscopically, the coexistence of classical low-grade and high-grade triple-negative components in breast AciCC is not uncommon. However, there is a scarcity of research on the comparative histopathological and genetic aspects of both components. Case presentation: A 34-year-old woman with a nontender mass in the upper outer quadrant of the left breast was initially diagnosed with a malignant small round cell tumor (undifferentiated or poorly differentiated carcinoma) based on a preoperative biopsy, which was later identified as breast AciCC with a high-grade solid component. Left breast-conserving surgery with sentinel lymph node biopsy was performed. Microscopically, the breast AciCC consisted of a classical acinic component and a high-grade component. The latter demonstrated a solid sheet-like pattern characterized by large, round, pleomorphic or vesicular nuclei, prominent nucleoli, and frequent mitotic activities. Classical acinic architectures focally merged together to form solid nests and transited into high-grade areas. Remarkably, in the high-grade lesion, conventional immunochemical markers for breast AciCC, such as α1-antitrypsin (AAT), Lysozyme (LYS), Epithelial membrane antigen (EMA), S100 protein (S100), and cytokeratin (CK) were negative, whereas cell cycle protein D1 (cyclin D1) and vimentin showed diffuse expression. Next‑generation sequencing (NGS) revealed that 43.5% of variants were identical in both components. Furthermore, PAK5 mutation; copy number (CN) loss of CDH1, CHEK1, and MLH1; and CN gains of CDK6, HGF, and FOXP1 were identified in the high-grade lesion. The patient was treated with eight cycles of adjuvant chemotherapy (epirubicin combined with cyclophosphamide) and radiotherapy after surgery, and she is currently alive for 43 months with no metastases or recurrences. Conclusions: This case demonstrates a comparative analysis of the histopathological and genetic characteristics of classical low-grade and high-grade components of AciCC within the same breast. This information may serve as a morphological and molecular basis for further investigation into the molecular mechanisms underlying high-grade lesions in breast AciCC.
- 24 July 2024
- Published by Springer Nature in Diagnostic Pathology
- Vol. 19 (1) , 1-8
Open AccessElucidating the nature of acinic cell carcinoma of the breast with high-grade morphology: evidence from case report
Background: Acinic cell carcinoma (AciCC) of the breast is a rare subtype of breast cancer. It was considered a low-grade triple-negative breast cancer (TNBC) with the potential to progress or transform into a high-grade lesion because of the molecular similarities with conventional aggressive TNBC in several genetic studies. Microscopically, the coexistence of classical low-grade and high-grade triple-negative components in breast AciCC is not uncommon. However, there is a scarcity of research on the comparative histopathological and genetic aspects of both components. Case presentation: A 34-year-old woman with a nontender mass in the upper outer quadrant of the left breast was initially diagnosed with a malignant small round cell tumor (undifferentiated or poorly differentiated carcinoma) based on a preoperative biopsy, which was later identified as breast AciCC with a high-grade solid component. Left breast-conserving surgery with sentinel lymph node biopsy was performed. Microscopically, the breast AciCC consisted of a classical acinic component and a high-grade component. The latter demonstrated a solid sheet-like pattern characterized by large, round, pleomorphic or vesicular nuclei, prominent nucleoli, and frequent mitotic activities. Classical acinic architectures focally merged together to form solid nests and transited into high-grade areas. Remarkably, in the high-grade lesion, conventional immunochemical markers for breast AciCC, such as α1-antitrypsin (AAT), Lysozyme (LYS), Epithelial membrane antigen (EMA), S100 protein (S100), and cytokeratin (CK) were negative, whereas cell cycle protein D1 (cyclin D1) and vimentin showed diffuse expression. Next‑generation sequencing (NGS) revealed that 43.5% of variants were identical in both components. Furthermore, PAK5 mutation; copy number (CN) loss of CDH1, CHEK1, and MLH1; and CN gains of CDK6, HGF, and FOXP1 were identified in the high-grade lesion. The patient was treated with eight cycles of adjuvant chemotherapy (epirubicin combined with cyclophosphamide) and radiotherapy after surgery, and she is currently alive for 43 months with no metastases or recurrences. Conclusions: This case demonstrates a comparative analysis of the histopathological and genetic characteristics of classical low-grade and high-grade components of AciCC within the same breast. This information may serve as a morphological and molecular basis for further investigation into the molecular mechanisms underlying high-grade lesions in breast AciCC.